Compare iShares MSCI Singapore ETF (EWS) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Singapore ETF vs TG Therapeutics Inc — how do they compare? iShares MSCI Singapore ETF trades at $31.84, while TG Therapeutics Inc trades at $54.86 (market cap $8.64B). Which is the better fit depends on your goals.
| EWS | TGTX | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $32.09 | $59.06 |
52-Week Low | $26.47 | $26.39 |
Market Cap | — | $8.64B |
Enterprise Value | — | $8.88B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
TG Therapeutics (TGTX) trades at $56.20, up 2.39% on the day, with a bullish technical signal and strong analyst consensus (84.6% buy ratings). The stock's momentum is supported by robust revenue growth, with 2025 revenue reaching $616.29M and net income of $447.18M, yielding impressive profitability margins (Gross Margin: 83.05%, ROE: 112.6%). Recent positive clinical updates for Briumvi in multiple sclerosis and schizophrenia trials have fueled investor optimism and media coverage.
The outlook remains positive due to Briumvi's commercial expansion and pipeline progress, though risks include earnings volatility (two recent misses), high valuation multiples (EV/EBITDA: 59.1), and clinical trial dependencies. The current price sits above the consensus price target of $48.50, suggesting near-term valuation concerns may limit upside unless operational execution continues to exceed expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About iShares MSCI Singapore ETF
EWS tracks the MSCI Singapore 25/50 Index, providing targeted exposure to large and mid-cap companies in Singapore. It is heavily weighted toward the financial, industrial, and real estate sectors, serving as a liquid tool for accessing Singapore's stable, dividend-oriented developed economy.
Read more on EWS →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
